Trading Halt
Released
Released
Announcement PDF
Market Announcement
22 June 2026
22 June 2026 Market Announcement 1/1
ASX Limited ASX Customer Service Centre 131 279 | asx.com.au
Avecho Biotechnology Limited (ASX: AVE) – Trading Halt
Trading in the securities of Avecho Biotechnology Limited (‘AVE’) will be halted at the request of AVE, pending
the release of an announcement by AVE.
Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:
• the commencement of normal trading on Wednesday, 24 June 2026; or
• the release of the announcement to the market.
AVE’s request for a trading halt is attached below for the information of the market.
Issued by
ASX Compliance
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmark Business Park, Clayton VIC Australia 3168 avecho.com.au
22 June 2026
Ms Melissa Kostopoulos
Senior Adviser
ASX Supervision
Level 45, South Tower
Rialto
525 Collins Street
Melbourne VIC 3000
(By email: tradinghaltsmelbourne@asx.com.au)
Dear Melissa,
REQUEST FOR TRADING HALT
Avecho Biotechnology Limited (ASX: AVE) (the Company) requests an immediate halt to the trading
of the Company’s ordinary shares quoted on the Australian Securities Exchange (ASX) in accordance
with ASX Listing Rule 17.1.
The trading halt is requested pending an announcement regarding the outcome of the interim analysis
for the Company’s Phase III trial evaluating its proprietary cannabidiol (CBD) TPM capsule for insomnia
(stated purpose).
In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation
to the request:
1. The trading halt is necessary to assist the Company in managing its continuous disclosure
obligations as the Company expects to make an announcement to the market in relation to the
stated purpose.
2. The Company requests that the trading halt remains in place until the earlier of commencement of
normal trading on Wednesday, 24 June 2026, or when the announcement regarding the stated
purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of
normal trading on Wednesday, 24 June 2026.
4. The Company is not aware of any reason why the trading halt should not be granted or of any
further information necessary to inform the market about the trading halt.
Please contact me if you require any further information concerning this matter.
Yours sincerely.
Naomi Lawrie
Company Secretary
Avecho Biotechnology Limited
Share your feedback
Discover